Santen Pharmaceutical
4536.TTSE PRIMEPharmaceutical
Filed as SANTEN PHARMACEUTICAL CO., LTD. (2022-06–2026-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥171.8bn | ¥188.1bn | ¥195.2bn | ¥196.6bn | ¥190.8bn | ¥186.1bn |
| Operating income | ¥20.5bn | ¥23.4bn | ¥28.0bn | ¥24.8bn | ¥21.4bn | ¥23.6bn |
| Ordinary income | ¥22.0bn | ¥26.2bn | ¥31.3bn | ¥27.1bn | ¥22.5bn | ¥25.3bn |
| Total assets | ¥231.5bn | ¥237.7bn | ¥271.8bn | ¥282.9bn | ¥363.8bn | ¥353.6bn |
| Net assets / equity | ¥127.0bn | ¥153.4bn | ¥187.5bn | ¥199.3bn | ¥297.5bn | ¥294.2bn |
| EPS (basic) | ¥48.18 | ¥51.03 | ¥50.88 | ¥-153.18 | ¥43.59 | ¥54.44 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 209 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 209 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 80 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 209 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 209 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 210 figures · EDINET |
21 more reports are still being processed.